An ELISA avoiding interference by heterophilic antibodies in the measurement of components of the plasminogen activation system in blood

被引:35
作者
Grebenchtchikov, N
Sweep, CGJ
Geurts-Moespot, A
Piffanelli, A
Foekens, JA
Benraad, TJ
机构
[1] Univ Nijmegen, Ctr Med, Dept Chem Endocrinol 530, Nijmegen, Netherlands
[2] Univ Ferrara, Dept Clin & Expt Med, Sect Nucl Med, Ferrara, Italy
[3] Rotterdam Canc Inst, Div Endocrine Oncol, Dept Med Oncol, Rotterdam, Netherlands
[4] Univ Rotterdam Hosp, Rotterdam, Netherlands
关键词
heterophilic antibodies; rheumatoid factor; ELISA; avian antibodies; serum; plasma;
D O I
10.1016/S0022-1759(02)00213-2
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Endogenous heterophilic antibodies in blood are known to interfere with two-site enzyme-linked immunosorbent assays (ELISAs) evoking false positive signals. In the present study, we describe an assay for the assessment of components of the plasminogen activation system (uPA, tPA and PAI-1, and their complexes) in blood which is not susceptible to interference by heterophilic antibodies. In the ELISA format, two avian (duck, chicken) antibodies are employed in the pre-analyte and two mammalian (rabbit, goat) antibodies in the post-analyte stage. The assay is compared to our earlier reported ELISA for measuring uPA, tPA and PAI-1 components in tumor tissue extracts. Applying the so-called "nonsense formats", designed against non-existent components, to the NIBSC reference preparation of rheumatoid factor (RF), no response was found with the new assay, whereas a clear RE dose-dependent interfering signal was observed with the original assay designed for tumor tissue extracts. Analysis of tumor-tissue based international reference preparations (RBG EORTC 10 1094 and 040297), human anti-mouse antibodies (HAMA) containing sera, and sera from patients with rheumatoid arthritis (RA), also displayed no false positive signals. In conclusion, we have developed an ELISA that permits the determination of blood levels of components in the urokinase system, free from disturbance by endogenous heterophilic antibodies. (C) 2002 Elsevier Science B.V All rights reserved.
引用
收藏
页码:219 / 231
页数:13
相关论文
共 37 条
[11]   UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND ITS INHIBITOR PAI-1 - PREDICTORS OF POOR RESPONSE TO TAMOXIFEN THERAPY IN RECURRENT BREAST-CANCER [J].
FOEKENS, JA ;
LOOK, MP ;
PETERS, HA ;
VANPUTTEN, WLJ ;
PORTENGEN, H ;
KLIJN, JGM .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (10) :751-756
[12]   A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols [J].
Grebenschikov, N ;
GeurtsMoespot, A ;
DeWitte, H ;
Heuvel, J ;
Leake, R ;
Sweep, F ;
Benraad, T .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 1997, 12 (01) :6-14
[13]  
Grebenschikov N, 1999, INT J CANCER, V81, P598, DOI 10.1002/(SICI)1097-0215(19990517)81:4<598::AID-IJC16>3.0.CO
[14]  
2-9
[15]  
GUILBERT B, 1982, J IMMUNOL, V128, P2779
[16]   Antibodies to DNA [J].
Hahn, BH .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (19) :1359-1368
[17]   Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer [J].
Hasui, Y ;
Marutsuka, K ;
Asada, Y ;
Osada, Y .
UROLOGY, 1996, 47 (01) :34-37
[18]   Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer [J].
Hofmann, R ;
Lehmer, A ;
Hartung, R ;
Robrecht, C ;
Buresch, M ;
Grothe, F .
JOURNAL OF UROLOGY, 1996, 155 (03) :858-862
[19]  
HUNTER WM, 1980, LANCET, V2, P1136
[20]   UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (U-PA) ANTIGEN IS A PREDICTOR OF EARLY RELAPSE IN BREAST-CANCER [J].
JANICKE, F ;
SCHMITT, M ;
HAFTER, R ;
HOLLRIEDER, A ;
BABIC, R ;
ULM, K ;
GOSSNER, W ;
GRAEFF, H .
FIBRINOLYSIS, 1990, 4 (02) :69-78